Orphan drugs revisited: Author's response [4]

QJM: An International Journal of Medicine

Volumn 99, Issue 5, 2006, Pages 350-351

  Hughes, D ^a  

^a BANGOR UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG LEGISLATION; DRUG RESEARCH; DRUG SAFETY; ECONOMIC EVALUATION; EUROPEAN UNION; FINANCIAL MANAGEMENT; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; LETTER; LONGITUDINAL STUDY; MEDICAL DECISION MAKING; PHARMACOGENETICS; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RARE DISEASE; REGISTER; REIMBURSEMENT; RISK MANAGEMENT; UNITED KINGDOM;

EID: 33646231273     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcl046     Document Type: Letter

References (6)

1. McCabe C, Tsuchiya A, Claxton K, Raftery J. Orphan drugs revisited. Q J Med 2006; 99:341-46.
2. Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: Do they deserve special status for funding? Q J Med 2005; 98:829-36.
3. McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: Should we value rarity? Br Med J 2005; 331:1016-19.
4. Hughes DA. Rationing of drugs for rare diseases. Pharmacoeconomics 2006; in press.
5. Martikainen J, Kivi I, Linnosmaa I. European prices of newly launched reimbursable pharmaceuticals-a pilot study. Health Policy 2005; 74:235-46.
6. Walley T, Earl-Slater A, Haycox A, Bagust A. An integrated national pharmaceutical policy for the United Kingdom? Br Med J 2000; 321:1523-6.